News

GTN and C4X Discovery Announce Partnership

29th Nov 2018- We are excited to announce our partnership with C4X Discovery Holdings plc (“C4XD”), a pioneering drug discovery company, initially focusing on identifying potential small molecule hits against a high-value neurodegeneration target.

Artificial Intelligence is expected to revolutionise the drug discovery industry. GTN is at the forefront of the field, using deep-learning techniques and quantum physics to simulate, filter and search for molecules that are hidden from traditional technologies. However, over-simplistic representation of molecules is a key challenge for the application of artificial intelligence to problems of medicinal chemistry, resulting in suboptimal property prediction and thus results. In order to address this “representation problem”, C4XD, using its conformational analysis platform Conformetrix, will provide GTN with world-leading molecular descriptors for use in its in-silico discovery platform. By combining both technologies, the collaboration will aim to unlock new areas of chemical space and identify novel small molecules.

This partnership is a great milestone for GTN as we expand the capabilities of our proprietary quantum machine learning platform.

Prof Noor Shaker, CEO of GTN, said: "We are excited to be working with C4X. GTN will deploy its platform to discover novel, high quality chemicals and accelerate the discovery process. Our unique approach to quantum representation of molecules and advance machine learning plays very nicely with C4XD's molecular descriptors. It is a key component of GTN's strategy to form close collaborations with biotechs and pharmaceutical companies and we hope that this is the start of a growing relationship with C4X. We are looking forward to a productive collaboration with C4X."

Dr Craig Fox, CSO of C4X Discovery, said: "Strategic partnerships represent a critical component of our strategy and we are delighted to be collaborating with GTN on this exciting project. Leveraging the clear synergies that exist between our Conformetrix platform and GTN’s in-silico discovery technology, we aim to solve the representation problem and enable pioneering research into unexplored chemical space against a commercially attractive neurodegeneration target. We are excited to be working with the team at GTN and are looking forward to seeing the results of this project."

See the full press release here.

As featured in:
PharmaTimes
Wired Focus
Web Financial Group
The Business Desk
Sharecast News
BIO World
Bio Portfolio